148967-82-2

Basic information

• Product Name: 3,3-dimethyl-1a,2,3,7b-tetrahydronaphtho[1,2-b]oxirene
• CAS NO: 148967-82-2
• Molecular Weight: 174.243
• Mol File: 148967-82-2.mol

Chemical Properties

• CAS DataBase Reference: 3,3-dimethyl-1a,2,3,7b-tetrahydronaphtho[1,2-b]oxirene(CAS DataBase Reference)
• NIST Chemistry Reference: 3,3-dimethyl-1a,2,3,7b-tetrahydronaphtho[1,2-b]oxirene(148967-82-2)
• EPA Substance Registry System: 3,3-dimethyl-1a,2,3,7b-tetrahydronaphtho[1,2-b]oxirene(148967-82-2)

Safety Data

• Hazardous Substances Data: 148967-82-2(Hazardous Substances Data)

Upstream product

• 2979-69-3 3,4-dihydro-4,4-dimethyl-1(2H)-naphthalenone 
• 53952-18-4 4,4-dimethyl-1,2,3,4-tetrahydronaphthalen-1-ol 
• 2733-79-1 1,2-dihydro-1,1-dimethylnaphthalene 

Downstream Products

• 1610344-92-7 1-((1R,2R)-2-hydroxy-4,4-dimethyl-1,2,3,4-tetrahydronaphthalen-1-yl)-3-(4-methyl-1-phenyl-3-(quinuclidin-3-yloxy)-1H-pyrazol-5-yl)urea 

Relevant articles and documents

CRYSTALS OF TETRAHYDRONAPHTHYL UREA DERIVATIVE

Provided are type I, III, V and VI crystals of 1-((1R,2R)-2-hydroxy-4,4-dimethyl-1,2,3,4-tetrahydronaphthalen-1-yl)-3-(5-methyl-6-(2-methylpyrimidin-5-yl)-2-phenylpyridin-3-yl)urea which are useful as bulk pharmaceutical crystals. Also provided are type I, III, V and VI crystals of 1-((1R,2R)-2-hydroxy-4,4-dimethyl-1,2,3,4-tetrahydronaphthalen-1-yl)-3-(5-methyl-6-(2-methylpyrimidin-5-yl)-2-phenylpyridin-3-yl)urea having excellent TrkA inhibitory effect, medicines and medicinal composition containing these crystals, and a method for producing these crystals.

NOVEL TETRAHYDRONAPHTHYL UREA DERIVATIVE

The present invention aims to provide a compound having a TrkA inhibitory action, a pharmaceutically acceptable salt thereof, or a solvate thereof, a pharmaceutical composition containing the same as an active ingredient, and a preventive and/or therapeutic agent for medicinal use, in particular for a disease in which TrkA in involved (pain, cancers, inflammation/inflammatory diseases, allergic diseases, skin diseases, neurodegenerative diseases, infectious diseases, Sjogren's syndrome, endometriosis, renal diseases, osteoporosis, and the like). Specifically, the present invention provides a compound or an optical isomer thereof, a pharmaceutically acceptable salt thereof, a solvate thereof, or the like, the compound represented by formula (I):

BICYCLIC UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF PAIN

Compounds of Formula I: or stereoisomers, tautomers, or pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein Ring A, Ring C and X are as defined herein, are inhibitors of TrkA kinase and are useful in the treatment of diseases which can be treated with a TrkA kinase inhibitor such as pain, cancer, inflammation/inflammatory diseases, neurodegenerative diseases, certain infectious diseases, Sjogren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis and pelvic pain syndrome.